C. difficile Hijacks Gut Nerve Peptides to Drive Inflammation — And Blocking Them Could Be a New Treatment | Research

The takeaway

C. difficile toxin B triggers gut inflammation by forcing neurons to release the neuropeptides substance P and CGRP, and blocking these peptides reduced tissue damage and bacterial burden in mice, suggesting a new therapeutic approach.

SP + CGRP
The two neuropeptides that C. difficile toxin B forces gut neurons to release, driving the destructive inflammation of CDI

What the researchers found

TcdB (toxin B) from C. difficile targets gut-innervating afferent neurons via Frizzled receptors (FZD1/2/7) and pericytes via CSPG4, stimulating secretion of substance P (SP) and CGRP from neurons and proinflammatory cytokines from pericytes. This drives neurogenic inflammation.

Key proof: selectively activating the TcdB enzymatic domain in sensory neurons alone was sufficient to cause major CDI-like colonic pathology. Conversely, mice lacking SP, CGRP, or the NK1R receptor showed reduced pathology. Blocking SP or CGRP signaling reduced both tissue damage and C. difficile bacterial burden in mice infected with standard and hypervirulent strains.

Why it matters

C. difficile infections kill thousands of people annually and are increasingly difficult to treat due to antibiotic resistance and high recurrence rates. Current treatments target the bacteria directly, but this study reveals that much of the damage comes from the body's own neuropeptide-driven inflammatory response. Blocking substance P or CGRP — for which drugs already exist (NK1R antagonists, CGRP antibodies) — could offer a completely new treatment strategy that targets the host response rather than the bacteria.

How the study worked

The researchers used a combination of in vitro cell biology, receptor identification, and in vivo mouse models. They identified TcdB receptors on neurons and pericytes, measured neuropeptide secretion, and used a novel 'toxogenetics' approach — delivering the TcdB enzymatic domain specifically to sensory neurons via a modified diphtheria toxin — to prove neurogenic inflammation is sufficient for CDI pathology. Knockout mice lacking SP, CGRP, or NK1R were used to confirm the role of these peptides. Pharmacological blockade of neuropeptide signaling was tested in C. difficile infection models including hypervirulent strains.

What this study cannot tell us

This is a mouse study, and the neurogenic inflammation mechanisms may not be identical in humans. The specific drug doses and administration routes for neuropeptide blockade in CDI patients would need to be established through clinical trials. The study demonstrates proof of concept but does not establish optimal treatment protocols. Whether neuropeptide blockade would be sufficient as monotherapy or needs to be combined with antibiotics is not addressed.

How to read the evidence

This is a high-impact preclinical study published in Nature with rigorous mechanistic data including knockout mice, novel toxogenetic approaches, and pharmacological validation. While the evidence is strong for basic science, clinical translation in humans has not yet been tested.

When this study was published

Published in 2023 in Nature, this is a recent and highly cited study that opens a new therapeutic avenue for C. difficile infections through neuropeptide targeting.

The bigger picture

This Nature paper reveals a paradigm-shifting mechanism: a bacterial infection deliberately co-opting the nervous system's neuropeptide signaling to create a favorable inflammatory environment. This connects C. difficile research to the rapidly growing field of neuroimmunology and the gut-brain axis. Remarkably, drugs targeting substance P (NK1R antagonists, currently used for chemotherapy-induced nausea) and CGRP (anti-CGRP antibodies, used for migraine) already exist and could potentially be repurposed for C. difficile infections.

Questions still open

Could existing NK1R antagonists (like aprepitant) or CGRP antibodies (like erenumab) be repurposed for C. difficile treatment in clinical trials?
Does neurogenic inflammation play a role in other gut infections beyond C. difficile?
Would combining neuropeptide blockade with standard antibiotic therapy improve C. difficile treatment outcomes more than either approach alone?

Common questions

How does a gut bacterium control nerves?

C. difficile produces toxin B, which latches onto specific receptors on the surface of gut neurons (Frizzled receptors) and blood vessel cells (CSPG4). Once inside these cells, the toxin forces neurons to release substance P and CGRP — neuropeptides that trigger intense inflammation. This inflammation actually helps the bacteria colonize the gut more effectively, so the bacterium is essentially hijacking the nervous system to create a more favorable environment for itself.

Could migraine drugs help treat C. difficile infections?

Potentially, yes. This study showed that blocking CGRP signaling — which is exactly what migraine drugs like erenumab do — reduced C. difficile-related tissue damage in mice. Similarly, NK1R antagonists used for chemotherapy-induced nausea block substance P signaling, which also helped in these experiments. Clinical trials would be needed to confirm this works in humans, but the existing safety data on these drugs could accelerate that process.

Read the original research

C. difficile intoxicates neurons and pericytes to drive neurogenic inflammation.

Nature, 622(7983), 611-618

View on PubMed ↗Publisher’s paper ↗

Citation

Manion, John; Musser, Melissa A; Kuziel, Gavin A; Liu, Min; Shepherd, Amy; Wang, Siyu; Lee, Pyung-Gang; Zhao, Leo; Zhang, Jie; Marreddy, Ravi K R; Goldsmith, Jeffrey D; Yuan, Ke; Hurdle, Julian G; Gerhard, Ralf; Jin, Rongsheng; Rakoff-Nahoum, Seth; Rao, Meenakshi; Dong, Min. (2023). C. difficile intoxicates neurons and pericytes to drive neurogenic inflammation.. Nature, 622(7983), 611-618. https://doi.org/10.1038/s41586-023-06607-2